<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55988">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377271</url>
  </required_header>
  <id_info>
    <org_study_id>2014-000848-14</org_study_id>
    <nct_id>NCT02377271</nct_id>
  </id_info>
  <brief_title>ENDOTHELION Study Group: Effect of Bosentan in NAION Patients</brief_title>
  <acronym>ENDOTHELION</acronym>
  <official_title>Effect of Bosentan in Patients With Non Arteritic Ischemic Optic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute ischemic optic neuropathy are the second leading cause of optic neuropathy after
      glaucoma in the population aged over 50 years. The visual prognosis of the condition is
      unfavorable in the great majority of cases, with significant effects on the visual field and
      vision. The severity of the unilateral condition is also associated with bilateralization in
      15% at 5 years. There is no effective treatment for the acute phase of the disease or to
      reduce the rate of bilateralization. In this context, it is essential to develop new
      therapeutic strategies in the acute phase of the disease to reduce the anatomical optic
      nerve damage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of our study will be to compare the treatment with bosentan to placebo
      for 8 weeks for recovery anatomical criteria (RFNL in OCT, optic atrophy) and functional
      (visual acuity, visual field). The primary endpoint will be the improvement of the visual
      field, a major criterion of the affected visual function in this disease.

      The evaluation of bosentan will mainly after 8 weeks of treatment in order to assess the
      effectiveness of drug treatment in the absence of continuous positive airway pressure (set
      up after three months if necessary, feasible confounding factor for the evaluation of
      results ), the period of three months is sufficient to assess the anatomical and functional
      recovery (disappearance of papilledema).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>automated visual field (Humphrey 30-2 SITA-standard)</measure>
    <time_frame>at 3 month visits</time_frame>
    <description>Humphrey 30-2 SITA-standard</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual acuity (ETDRS scale)</measure>
    <time_frame>at 3 month</time_frame>
    <description>ETDRS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>optic nerve fiber layer thickness</measure>
    <time_frame>at 3 month</time_frame>
    <description>OCT measurement</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Endothelial function by measuring the peripheral arterial tone (PAT)</measure>
    <time_frame>3 month visit</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Ischemic Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bosentan at a dose of 125 mg two times daily, will be administered orally, twice a day, during eight weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo drug , twice a day, during eight weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
    <description>treatment by bosentan or placebo is randomized , 125 mg twice a day</description>
    <arm_group_label>Bosentan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>treatment by bosentan or placebo is randomized</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non arteritic ischemic optic neuropathy (NAION) with onset &lt; 21 days

        Exclusion Criteria:

          -  pregnant woman

          -  other intercurrent ocular pathology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Pr CHIQUET, Prof, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christophe Pr CHIQUET, Prof, MD, PhD</last_name>
    <email>CChiquet@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Baidi Zineb, PhD</last_name>
    <phone>+33 476766660</phone>
    <email>ZBaidi@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dan MILEA, MD</last_name>
      <phone>0241353274</phone>
      <email>dmilea@free.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie LERUEZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric GAGNADOUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascaline PRIOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Bénédicte ROUGIER, MD</last_name>
      <phone>05 57 82 12 16</phone>
      <email>marie-benedicte.rougier@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-François KOROBELNIK, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre PHILIP, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Grenoble Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe CHIQUET, MD</last_name>
      <phone>04 76 76 55 16</phone>
      <email>CChiquet@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Florent APTEL, MD</last_name>
      <phone>04 76 76 55 48</phone>
      <email>faptel@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Paul ROMANET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Louis PEPIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renaud TAMISIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine LAUNOIS-ROLLINAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick LEVY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertrand TOUSSAINT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier ORMEZZANO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carole BURILLON, MD</last_name>
      <phone>0472116217</phone>
      <email>carole.burillon@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Lucie ABOUAF, MD</last_name>
      <email>carole.burillon@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Frédéric GORMAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvain BECCAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ophtalmological fondation of Rothschild + Bichat Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital of Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe GAIN, MD</last_name>
      <phone>0477127793</phone>
      <email>philippe.gain@univ-st-etienne.fr</email>
    </contact>
    <contact_backup>
      <last_name>Claire GUILLEMOT, MD</last_name>
      <phone>0673169519</phone>
      <email>claire.guillemot@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gilles THURET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle COURT-FORTUNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>February 24, 2015</lastchanged_date>
  <firstreceived_date>December 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bosentan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Neuropathy, Ischemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
